Concepts (244)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Food Hypersensitivity | 58 | 2026 | 186 | 23.820 |
Why?
|
| Desensitization, Immunologic | 46 | 2026 | 117 | 13.660 |
Why?
|
| Peanut Hypersensitivity | 32 | 2026 | 88 | 10.510 |
Why?
|
| Anaphylaxis | 24 | 2026 | 93 | 9.670 |
Why?
|
| Allergens | 46 | 2026 | 344 | 7.740 |
Why?
|
| Milk Hypersensitivity | 6 | 2024 | 18 | 3.940 |
Why?
|
| Arachis | 21 | 2026 | 76 | 3.290 |
Why?
|
| Omalizumab | 11 | 2026 | 41 | 3.050 |
Why?
|
| Egg Hypersensitivity | 5 | 2024 | 12 | 3.030 |
Why?
|
| Epinephrine | 10 | 2026 | 150 | 2.830 |
Why?
|
| Anti-Allergic Agents | 8 | 2026 | 28 | 2.670 |
Why?
|
| Administration, Oral | 25 | 2024 | 709 | 2.610 |
Why?
|
| Skin Tests | 13 | 2024 | 100 | 2.550 |
Why?
|
| Hypersensitivity | 10 | 2025 | 226 | 2.220 |
Why?
|
| Milk | 6 | 2024 | 111 | 2.090 |
Why?
|
| Quality of Life | 13 | 2025 | 2076 | 2.070 |
Why?
|
| Enterocolitis | 5 | 2025 | 30 | 1.990 |
Why?
|
| Immunotherapy | 12 | 2023 | 761 | 1.970 |
Why?
|
| Nuts | 5 | 2021 | 15 | 1.600 |
Why?
|
| Humans | 122 | 2026 | 130488 | 1.520 |
Why?
|
| Dietary Proteins | 3 | 2025 | 221 | 1.490 |
Why?
|
| Drug Hypersensitivity | 2 | 2024 | 99 | 1.480 |
Why?
|
| Eggs | 6 | 2024 | 23 | 1.480 |
Why?
|
| Social Media | 3 | 2024 | 120 | 1.470 |
Why?
|
| Asthma | 7 | 2025 | 922 | 1.340 |
Why?
|
| Child | 45 | 2026 | 26207 | 1.230 |
Why?
|
| Allergy and Immunology | 6 | 2025 | 30 | 1.160 |
Why?
|
| Insect Bites and Stings | 3 | 2025 | 41 | 1.120 |
Why?
|
| Food | 9 | 2024 | 121 | 1.120 |
Why?
|
| Immunoglobulin E | 13 | 2025 | 215 | 1.060 |
Why?
|
| Child, Preschool | 25 | 2026 | 15010 | 0.960 |
Why?
|
| Nut Hypersensitivity | 4 | 2021 | 8 | 0.950 |
Why?
|
| Proctocolitis | 1 | 2024 | 1 | 0.880 |
Why?
|
| Immune Tolerance | 4 | 2024 | 153 | 0.870 |
Why?
|
| Arthropod Venoms | 2 | 2025 | 7 | 0.860 |
Why?
|
| Decision Support Techniques | 2 | 2024 | 293 | 0.850 |
Why?
|
| Allergists | 4 | 2026 | 9 | 0.850 |
Why?
|
| Ants | 1 | 2023 | 7 | 0.800 |
Why?
|
| Foodborne Diseases | 1 | 2023 | 13 | 0.780 |
Why?
|
| Fabaceae | 1 | 2022 | 17 | 0.750 |
Why?
|
| Infant | 19 | 2026 | 13288 | 0.730 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2024 | 221 | 0.710 |
Why?
|
| Plant Proteins | 2 | 2018 | 86 | 0.680 |
Why?
|
| Adolescent | 22 | 2025 | 20805 | 0.670 |
Why?
|
| Decision Making | 2 | 2023 | 711 | 0.640 |
Why?
|
| Sesamum | 1 | 2019 | 3 | 0.590 |
Why?
|
| Pathology, Molecular | 1 | 2019 | 61 | 0.580 |
Why?
|
| Lupinus | 1 | 2018 | 1 | 0.580 |
Why?
|
| Biological Factors | 1 | 2018 | 26 | 0.570 |
Why?
|
| Patient Care Management | 1 | 2018 | 61 | 0.540 |
Why?
|
| Mouth | 2 | 2016 | 69 | 0.530 |
Why?
|
| Attitude to Health | 1 | 2019 | 246 | 0.520 |
Why?
|
| United States | 12 | 2026 | 11882 | 0.510 |
Why?
|
| Female | 31 | 2026 | 70404 | 0.500 |
Why?
|
| Biological Products | 3 | 2026 | 143 | 0.500 |
Why?
|
| Male | 29 | 2026 | 64516 | 0.490 |
Why?
|
| Parents | 1 | 2024 | 1117 | 0.480 |
Why?
|
| Animals | 14 | 2026 | 33700 | 0.480 |
Why?
|
| Patient Participation | 3 | 2024 | 251 | 0.460 |
Why?
|
| Cooking | 3 | 2024 | 37 | 0.430 |
Why?
|
| Cost-Benefit Analysis | 6 | 2026 | 547 | 0.410 |
Why?
|
| Emergency Medical Services | 4 | 2025 | 387 | 0.400 |
Why?
|
| Physicians | 1 | 2020 | 634 | 0.400 |
Why?
|
| Immunologic Factors | 4 | 2022 | 190 | 0.390 |
Why?
|
| Administration, Cutaneous | 2 | 2025 | 63 | 0.390 |
Why?
|
| Surveys and Questionnaires | 5 | 2025 | 4043 | 0.380 |
Why?
|
| Disease Management | 4 | 2025 | 555 | 0.380 |
Why?
|
| Sublingual Immunotherapy | 2 | 2023 | 5 | 0.370 |
Why?
|
| Antigens, Plant | 2 | 2024 | 35 | 0.360 |
Why?
|
| Practice Guidelines as Topic | 3 | 2025 | 1288 | 0.360 |
Why?
|
| Eosinophilic Esophagitis | 2 | 2024 | 77 | 0.340 |
Why?
|
| Mental Health | 2 | 2025 | 370 | 0.340 |
Why?
|
| Cattle | 2 | 2023 | 500 | 0.340 |
Why?
|
| Hot Temperature | 2 | 2024 | 139 | 0.330 |
Why?
|
| Treatment Outcome | 7 | 2025 | 12877 | 0.320 |
Why?
|
| Delivery, Obstetric | 1 | 2012 | 257 | 0.320 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2012 | 350 | 0.300 |
Why?
|
| Pediatrics | 1 | 2018 | 1242 | 0.280 |
Why?
|
| Risk Factors | 8 | 2026 | 10970 | 0.280 |
Why?
|
| Medication Adherence | 1 | 2012 | 336 | 0.280 |
Why?
|
| Prenatal Diagnosis | 1 | 2012 | 611 | 0.270 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2025 | 127 | 0.270 |
Why?
|
| Clinical Decision-Making | 2 | 2021 | 311 | 0.260 |
Why?
|
| Rhinitis, Allergic | 2 | 2025 | 19 | 0.250 |
Why?
|
| Mental Disorders | 2 | 2025 | 901 | 0.250 |
Why?
|
| Injections, Intramuscular | 2 | 2024 | 185 | 0.250 |
Why?
|
| United Kingdom | 2 | 2020 | 254 | 0.240 |
Why?
|
| Delphi Technique | 2 | 2024 | 275 | 0.230 |
Why?
|
| Bronchodilator Agents | 2 | 2026 | 156 | 0.230 |
Why?
|
| Inventions | 1 | 2025 | 19 | 0.230 |
Why?
|
| Syndrome | 2 | 2025 | 1157 | 0.220 |
Why?
|
| Education, Medical, Continuing | 1 | 2026 | 131 | 0.220 |
Why?
|
| Negotiating | 1 | 2025 | 13 | 0.220 |
Why?
|
| Empathy | 1 | 2025 | 69 | 0.220 |
Why?
|
| North America | 1 | 2025 | 256 | 0.210 |
Why?
|
| Motivational Interviewing | 1 | 2025 | 51 | 0.210 |
Why?
|
| Powders | 1 | 2024 | 24 | 0.210 |
Why?
|
| Burnout, Professional | 1 | 2026 | 134 | 0.200 |
Why?
|
| Injections | 1 | 2023 | 110 | 0.200 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2023 | 31 | 0.190 |
Why?
|
| Food, Formulated | 1 | 2023 | 38 | 0.190 |
Why?
|
| Milk Proteins | 1 | 2023 | 95 | 0.190 |
Why?
|
| Penicillins | 1 | 2023 | 153 | 0.190 |
Why?
|
| United States Food and Drug Administration | 2 | 2020 | 154 | 0.190 |
Why?
|
| Patient-Centered Care | 1 | 2025 | 237 | 0.190 |
Why?
|
| Sleep Wake Disorders | 1 | 2025 | 202 | 0.190 |
Why?
|
| Infant Formula | 1 | 2023 | 105 | 0.180 |
Why?
|
| Skin | 1 | 2025 | 538 | 0.180 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2024 | 832 | 0.180 |
Why?
|
| Informed Consent | 1 | 2024 | 352 | 0.170 |
Why?
|
| Leadership | 1 | 2023 | 245 | 0.160 |
Why?
|
| Heart Defects, Congenital | 1 | 2012 | 1880 | 0.160 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 350 | 0.160 |
Why?
|
| Markov Chains | 3 | 2026 | 101 | 0.160 |
Why?
|
| Patient Compliance | 1 | 2023 | 460 | 0.160 |
Why?
|
| Substance-Related Disorders | 1 | 2025 | 489 | 0.160 |
Why?
|
| Adult | 5 | 2025 | 31140 | 0.160 |
Why?
|
| Symptom Assessment | 2 | 2017 | 109 | 0.160 |
Why?
|
| Patient Care Team | 1 | 2024 | 559 | 0.160 |
Why?
|
| Mass Screening | 1 | 2026 | 813 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 567 | 0.150 |
Why?
|
| Antibodies, Blocking | 1 | 2019 | 47 | 0.150 |
Why?
|
| Vaccines | 1 | 2024 | 385 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 509 | 0.150 |
Why?
|
| False Positive Reactions | 1 | 2019 | 142 | 0.150 |
Why?
|
| Infant, Newborn | 3 | 2019 | 8560 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 1272 | 0.140 |
Why?
|
| Fruit | 1 | 2020 | 228 | 0.140 |
Why?
|
| Pasteurellaceae | 1 | 2018 | 4 | 0.140 |
Why?
|
| Clostridiaceae | 1 | 2018 | 5 | 0.140 |
Why?
|
| Actinomycetaceae | 1 | 2018 | 6 | 0.140 |
Why?
|
| Anxiety | 1 | 2025 | 1006 | 0.140 |
Why?
|
| Caregivers | 1 | 2024 | 583 | 0.140 |
Why?
|
| Cross Reactions | 1 | 2018 | 159 | 0.140 |
Why?
|
| Carrier Proteins | 1 | 2023 | 997 | 0.130 |
Why?
|
| Probiotics | 2 | 2025 | 227 | 0.130 |
Why?
|
| Health Personnel | 1 | 2022 | 548 | 0.130 |
Why?
|
| Patient Selection | 1 | 2020 | 725 | 0.120 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 2897 | 0.120 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2018 | 378 | 0.120 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 250 | 0.120 |
Why?
|
| Prospective Studies | 3 | 2019 | 6435 | 0.120 |
Why?
|
| Depression | 1 | 2025 | 1310 | 0.120 |
Why?
|
| Immunity, Cellular | 1 | 2016 | 197 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2019 | 1242 | 0.110 |
Why?
|
| Food Labeling | 1 | 2014 | 11 | 0.110 |
Why?
|
| Pandemics | 1 | 2022 | 1156 | 0.110 |
Why?
|
| Double-Blind Method | 4 | 2022 | 1621 | 0.110 |
Why?
|
| Weaning | 1 | 2014 | 52 | 0.110 |
Why?
|
| Administration, Sublingual | 2 | 2024 | 14 | 0.110 |
Why?
|
| Infant Food | 1 | 2014 | 74 | 0.110 |
Why?
|
| Feces | 1 | 2018 | 720 | 0.110 |
Why?
|
| Risk Management | 1 | 2014 | 66 | 0.100 |
Why?
|
| England | 1 | 2014 | 57 | 0.100 |
Why?
|
| Early Diagnosis | 1 | 2014 | 191 | 0.100 |
Why?
|
| Adjuvants, Immunologic | 1 | 2015 | 393 | 0.100 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2013 | 9 | 0.100 |
Why?
|
| Cross-Over Studies | 1 | 2014 | 320 | 0.090 |
Why?
|
| Skin Temperature | 1 | 2012 | 17 | 0.090 |
Why?
|
| Thermography | 1 | 2012 | 12 | 0.090 |
Why?
|
| Specialization | 1 | 2012 | 75 | 0.090 |
Why?
|
| Pulmonary Medicine | 1 | 2012 | 33 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2021 | 3689 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 2578 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2024 | 17563 | 0.080 |
Why?
|
| Nose | 1 | 2012 | 114 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 2100 | 0.080 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2012 | 134 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 3794 | 0.080 |
Why?
|
| Young Adult | 2 | 2021 | 10009 | 0.080 |
Why?
|
| Delivery of Health Care | 2 | 2025 | 683 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2012 | 388 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 1167 | 0.070 |
Why?
|
| Anacardium | 1 | 2007 | 4 | 0.070 |
Why?
|
| Diet | 2 | 2024 | 1099 | 0.070 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2023 | 331 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 3028 | 0.060 |
Why?
|
| Primary Health Care | 1 | 2012 | 768 | 0.060 |
Why?
|
| Emergency Service, Hospital | 2 | 2024 | 1221 | 0.060 |
Why?
|
| Pediatricians | 1 | 2026 | 76 | 0.060 |
Why?
|
| Administration, Intranasal | 1 | 2024 | 130 | 0.050 |
Why?
|
| Self Administration | 1 | 2024 | 49 | 0.050 |
Why?
|
| Clinical Medicine | 1 | 2024 | 20 | 0.050 |
Why?
|
| Mass Media | 1 | 2024 | 28 | 0.050 |
Why?
|
| Patient Advocacy | 1 | 2024 | 60 | 0.050 |
Why?
|
| Administration, Inhalation | 1 | 2024 | 192 | 0.050 |
Why?
|
| Organizational Culture | 1 | 2024 | 94 | 0.050 |
Why?
|
| Excipients | 1 | 2023 | 13 | 0.050 |
Why?
|
| Dermatitis, Atopic | 1 | 2024 | 56 | 0.050 |
Why?
|
| Vitamins | 1 | 2024 | 112 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2024 | 222 | 0.050 |
Why?
|
| Prognosis | 1 | 2012 | 4867 | 0.050 |
Why?
|
| Managed Care Programs | 1 | 2023 | 54 | 0.050 |
Why?
|
| Nutritional Status | 1 | 2024 | 302 | 0.050 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2025 | 239 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2025 | 406 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2025 | 640 | 0.040 |
Why?
|
| Corylus | 1 | 2021 | 1 | 0.040 |
Why?
|
| Eczema | 1 | 2021 | 35 | 0.040 |
Why?
|
| Medicaid | 1 | 2023 | 251 | 0.040 |
Why?
|
| Comorbidity | 1 | 2025 | 1583 | 0.040 |
Why?
|
| Communication | 1 | 2024 | 540 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2024 | 438 | 0.040 |
Why?
|
| Pregnancy | 1 | 2012 | 7405 | 0.040 |
Why?
|
| Triticum | 1 | 2019 | 29 | 0.040 |
Why?
|
| Policy Making | 1 | 2019 | 60 | 0.040 |
Why?
|
| Government Regulation | 1 | 2019 | 44 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2022 | 435 | 0.040 |
Why?
|
| Academies and Institutes | 1 | 2019 | 81 | 0.040 |
Why?
|
| Mice | 1 | 2016 | 18173 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2023 | 5165 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2019 | 148 | 0.040 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2018 | 92 | 0.040 |
Why?
|
| Vaccination | 1 | 2024 | 1056 | 0.040 |
Why?
|
| Incidence | 1 | 2026 | 3321 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 698 | 0.030 |
Why?
|
| Gene-Environment Interaction | 1 | 2018 | 127 | 0.030 |
Why?
|
| Siblings | 1 | 2018 | 202 | 0.030 |
Why?
|
| Diet Therapy | 1 | 2017 | 40 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2017 | 164 | 0.030 |
Why?
|
| Recurrence | 1 | 2021 | 1478 | 0.030 |
Why?
|
| Lung | 1 | 2024 | 1537 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2017 | 293 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 337 | 0.030 |
Why?
|
| Hospitalization | 1 | 2023 | 1939 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 460 | 0.030 |
Why?
|
| Histamine H1 Antagonists, Non-Sedating | 1 | 2013 | 3 | 0.020 |
Why?
|
| Leukotriene Antagonists | 1 | 2013 | 15 | 0.020 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2013 | 60 | 0.020 |
Why?
|
| Phenotype | 1 | 2022 | 4465 | 0.020 |
Why?
|
| Age Factors | 1 | 2018 | 2827 | 0.020 |
Why?
|
| Middle Aged | 2 | 2025 | 28383 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 303 | 0.020 |
Why?
|
| Prevalence | 1 | 2017 | 2686 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 610 | 0.020 |
Why?
|
| Histamine H1 Antagonists | 1 | 2007 | 13 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 1874 | 0.020 |
Why?
|
| Urticaria | 1 | 2007 | 19 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 724 | 0.020 |
Why?
|
| Respiratory Sounds | 1 | 2007 | 78 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1484 | 0.020 |
Why?
|
| Dyspnea | 1 | 2007 | 159 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2007 | 1210 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2007 | 3352 | 0.010 |
Why?
|